Back to Browse Journals » Patient Preference and Adherence » Volume 2

Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial

Authors Sunanda Kane, William Holderman, Peter Jacques, Todd Miodek

Published 22 September 2008 Volume 2008:2 Pages 253—258


Review by Single-blind

Peer reviewer comments 2

Sunanda Kane1, William Holderman2, Peter Jacques2, Todd Miodek3

1Mayo Clinic College of Medicine, Rochester, MN, USA; 2Digestive Health Specialists, Tacoma, WA, USA; 3University of Chicago, Chicago, IL, USA

Background and Aims: Multiple studies have demonstrated the efficacy of aminosalicylates in maintaining remission in ulcerative colitis (UC). A newer formulation of mesalamine can be administered once daily. We aimed to examine the efficacy and tolerability of pH-dependent mesalamine for long-term maintenance, and compare the rates of medication consumption between groups over a prolonged period.

Methods: Subjects whose UC had been quiescent for at least 4 months, and who had been receiving mesalamine for maintenance only, were randomized to once daily or conventional dosing for 12 months. Disease activity and medication consumption was assessed every 3 months. The primary endpoint was the percentage of those with quiescent disease at 12 months.

Results: We enrolled 20 patients, 12 to once daily and 8 to conventional dosing. Six of the 12 patients (50%) in the once daily group compared with 5 of the 8 patients (62.5%) in the conventional group experienced a flare (p = 0.31). Only 5 of the 12 (42%) patients in the once daily group were adherent compared with 3 of 8 patients (37.5%) in the conventional dosing group (p = NS). Median amount consumed in the once daily group was 63% (range 0%–100%) and in the conventional group 55% (range 0%–100%), (p > 0.5). None of the adherent subjects in the once daily group experienced a flare, while 6 out of 7 (86%) who were non-adherent experienced a flare (p < 0.01). In the conventional dosing group, 1 in 3 adherent patients (33%) experienced a fl are compared with 4 out of 5 (80%) in the non-adherent group (p < 0.01).

Conclusion: Adherence, rather than medication regimen, appeared to be important in disease outcome at 12 months.

Keywords: ulcerative colitis, mesalamine, aminosalicylates, remission

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other articles by this author:

Optimizing use of 5-ASA in the treatment of ulcerative colitis: Focus on patient compliance and adherence

Steven J Bernick, Sunanda Kane

Patient Related Outcome Measures 2010, 1:57-63

Published Date: 15 June 2010

Readers of this article also read:

Adverse reaction to ceftriaxone in a 28-day-old infant undergoing urgent craniotomy due to epidural hematoma: review of neonatal biliary pseudolithiasis

Bartkowska-Śniatkowska A, Jończyk-Potoczna K, Zielińska M, Rosada-Kurasińska J

Therapeutics and Clinical Risk Management 2015, 11:1035-1041

Published Date: 2 July 2015

Intramedullary versus extramedullary fixation in the management of subtrochanteric femur fractures: a meta-analysis

Liu PC, Wu X, Shi H, Liu R, Shu HX, Gong JP, Yang Y, Sun Q, Wu JZ, Nie XY, Cai M

Clinical Interventions in Aging 2015, 10:803-811

Published Date: 28 April 2015

Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals

Farazuddin M, Dua B, Zia Q, Khan AA, Joshi B, Owais M

International Journal of Nanomedicine 2014, 9:1139-1152

Published Date: 3 March 2014

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients

Nielsen SA, McDonald MB, Majmudar PA

Clinical Ophthalmology 2013, 7:725-726

Published Date: 15 April 2013

Impact of household food insecurity on the nutritional status and the response to therapeutic feeding of people living with human immunodeficiency virus

Bahwere P, Deconinck H, Banda T, Mtimuni A, Collins S

Patient Preference and Adherence 2011, 5:619-627

Published Date: 16 December 2011

Beliefs that influence cost-related medication non-adherence among the “haves” and “have nots” with chronic diseases

Piette JD, Beard A, Rosland AM, McHorney CA

Patient Preference and Adherence 2011, 5:389-396

Published Date: 3 August 2011

The utility of an electronic adherence assessment device in type 2 diabetes mellitus: a pilot study of single medication

Nadir Kheir, William Greer, Adil Yousif, et al

Patient Preference and Adherence 2010, 4:247-254

Published Date: 7 July 2010